ডেনমার্ক -
ডেনিশ -
Lægemiddelstyrelsen (Danish Medicines Agency)
rosuvastatin "stada" 40 mg filmovertrukne tabletter
stada arzneimittel ag - rosuvastatin calcium - filmovertrukne tabletter - 40 mg
ডেনমার্ক -
ডেনিশ -
SEGES Landbrug & Fødevarer
agil 100 ec emulsionskoncentrat
adama northern europe b.v. - propaquizafop - emulsionskoncentrat - 100 g/l propaquizafop
ডেনমার্ক -
ডেনিশ -
SEGES Landbrug & Fødevarer
calaris suspensionskoncentrat
syngenta nordics a/s - mesotrion, terbuthylazin - suspensionskoncentrat - 70 g/l mesotrion ; 330 g/l terbuthylazin
ডেনমার্ক -
ডেনিশ -
SEGES Landbrug & Fødevarer
zetrola emulsionskoncentrat
adama northern europe b.v. - propaquizafop - emulsionskoncentrat - 100 g/l propaquizafop
ইউরোপীয় ইউনিয়ন -
ডেনিশ -
EMA (European Medicines Agency)
tremfya
janssen-cilag international nv - guselkumab - psoriasis - immunosuppressiva - plaque psoriasis tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritis tremfya, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (dmard) therapy (see section 5.
ইউরোপীয় ইউনিয়ন -
ডেনিশ -
EMA (European Medicines Agency)
vyxeos liposomal (previously known as vyxeos)
jazz pharmaceuticals ireland limited - daunorubicin hydrochloride, cytarabine - leukæmi, myeloid, akut - antineoplastiske midler - vyxeos liposomal er indiceret til behandling af voksne med nyligt diagnosticeret, terapi-relateret akut myeloid leukæmi (t-aml) eller aml med myelodysplastisk-relaterede ændringer (aml-mrc).
ইউরোপীয় ইউনিয়ন -
ডেনিশ -
EMA (European Medicines Agency)
skyrizi
abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - immunosuppressiva - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.